What is Predictive Biomarkers?

A predictive biomarker is a measure of the likelihood of a response or lack of response to a particular therapy. It allows the identification of patients most likely to benefit from a given therapy, thereby identifying potential markers and guiding the development/use of tailored therapies. The identification and use of predictive biomarkers has become an integral part of the drug discovery and development process. Identifying predictive biomarkers during the preclinical drug development process can have many benefits, and ultimately can reduce the potential risk of clinical trials. Build an optimal biomarker discovery platform by implementing a systems biology approach and utilizing a variety of preclinical models combined with robust analytical techniques. This could speed up drug development and hopefully increase the chances of clinical trials.

Fig. 1. Summary of the main predictive biomarkers of the anti-ranibizumab treatment response described in whole blood, mononuclear blood cells, plasma, saliva and aqueous humor samples. (Bobadilla M, et al., 2022)

Our Services

The high attrition rate of drugs in clinical development requires a new strategy to overcome it-the development and validation of robust and sensitive biomarkers early in drug development. As an ophthalmology preclinical CRO, Ace Therapeutics' capabilities in ophthalmology drug development include biomarker discovery, identification, validation, and quantitative analysis of primary cells and disease tissues, pharmacodynamics, and disease models.

When a brand-new drug with therapeutic potential is developed, Ace Therapeutics will offer a range of services to identify predictive biomarkers based on preclinical translational models and robust assays. This will enable customers to avoid the high attrition rate of drugs that can occur during clinical translation. Our researchers use preclinical translational models to gain insight into the mechanism of action and pharmacodynamic response of compounds, to identify the most promising therapeutic options for clients at the earliest stages of drug development, and to develop new personalities therapy for specific indications and patients.

Here we provide our clients with comprehensive predictive biomarker identification services via employing a range of in vitro screening methods (from cell line models to live animal models), as well as more in-depth functional and mechanistic studies.

Strategy

Our general strategy is using a large number of well-characterized cell line models of ophthalmic disease and a range of assays to understand the genetics of the response and develop potential biomarkers to guide future selection of live animal models, followed via live animal models to identify predictive biomarkers.

Our ocular predictive biomarker identification services are implemented by linking pharmacological screening data with genomic baseline information such as gene expression, gene mutation and copy number variation data, and pathway/network activation information, including:

• Single-gene analysis: Our scientists use genomics to identify individual genes whose mutation status correlates with sensitivity.
• Predictive biomarker generation: Our expert team constructs a multigene biomarker set that can predict drug sensitivity through in vitro living animal models.
• Bioinformatics analysis: Our data analysts characterize the genome/pathway composition of sensitive and insensitive cell lines, as well as support various data analysis methods.

What attracts our customers is that our services are all customized according to the customer's project development. This includes screening specific live animal models for different eye diseases, including mice, rats, dogs, rabbits and zebrafish. Contact us to accelerate the development of your project.

Our Experience

• Translated clinical biomarker analyses for multiple client projects.
• Provide a variety of in vitro living animal models, and develop customized models according to customers' project.
• The scope of services covers a variety of diseases in ophthalmology.
• The support of multiple omics technologies.
• Advanced analytics platform.

Thanks to its strong professional knowledge and advanced technology platform, Ace Therapeutics offers comprehensive predictive biomarker identification services. Our professional biomarker service team will determine the most appropriate solution for your project based on your specific requirements. If you are interested in our services, please feel free to contact us.

Reference

1. Bobadilla M, Pariente A, Oca AI, et al. Biomarkers as Predictive Factors of Anti-VEGF Response. Biomedicines. 2022;10(5):1003.

• Omics-Based Ocular Biomarker Discovery and Analysis Services
• Ocular Matrix Biomarker Discovery and Analysis Services
• Ocular Imaging Biomarker Services
• Ocular Prognosis Biomarker Services
• Ocular Transformational Biomarker Services
• Ocular Pharmacodynamic Biomarker Services
• Custom Ocular Biomarker Development Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit